A year's course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations -- cutting the rate of exacerbations by a third to a half compared with ...

Age, asthma diagnosis, number of exacerbations, and number of benralizumab treatment records within specified periods were used to identify a total of 1795 participants for inclusion in the study.

Receiving a benralizumab injection during an acute asthma or COPD exacerbation with a blood eosinophil count of at least 300 cells/µL led to fewertreatment failures, according to results ...

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if used to treat acute asthma attacks, calling it the first major advance for this aspect of the disease in 50 ...

Mepolizumab and benralizumab are highly effective for patients with severe eosinophilic asthma, according to a study presented at the American Thoracic Society (ATS) International Conference 2022 ...

Treatment with benralizumab in adults with severe, uncontrolled asthma was well tolerated for up to 5 years, with a long-term safety profile consistent with previous phase 3 trials.The data come ...

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following promising clinical trial data.

Bafadhel's team randomly assigned more than 150 asthma and COPD patients being treated in emergency departments of English ...

A new treatment for asthma attacks is being described as “game-changing” by the London scientists who created it. The drug, ...

In CHRONICLE trial findings presented at ACAAI 2021, patients with severe asthma on benralizumab had fewer exacerbations, ED visits, and hospitalizations.

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial, The Lancet Respiratory Medicine.

A year's course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations - cutting the rate of exacerbations by a third to a half compared with placebo ...